08:45 EDT Viking Therapeutics up 14% at $79.10 in pre-market after Phase 1 data for VK2735
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Clarifies Regulatory Disclosure Status
- Approval of Madrigal’s Rezdiffra positive for Viking and MASH space, says Stifel
- Viking Therapeutics price target raised to $100 from $86 at BTIG
- Novo results raising the bar for Viking’s oral VK2735, says Oppenheimer
- Viking Therapeutics initiated with a Buy at Jefferies
